Tumor-intrinsic resistance mechanisms to immune checkpoint inhibitor therapy included PD-L1 expression, mutational burden, neoantigen expression, epigenetic variations, type II interferon signaling, and antigen presentation pathways. This evidence concerns the gene CD274 and neoplasm.